Cargando…

Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization

SIMPLE SUMMARY: The rate of total tumor engraftment of patient-derived xenografts is 50% in cervical cancer. These cancers retain their histopathological characteristics. The gene mutations and expression patterns associated with carcinogenesis and infiltration and the expression levels of genes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyamoto, Shunsuke, Tanaka, Tomohito, Hirosuna, Kensuke, Nishie, Ruri, Ueda, Shoko, Hashida, Sousuke, Terada, Shinichi, Konishi, Hiromi, Kogata, Yuhei, Taniguchi, Kohei, Komura, Kazumasa, Ohmichi, Masahide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221029/
https://www.ncbi.nlm.nih.gov/pubmed/35740635
http://dx.doi.org/10.3390/cancers14122969
_version_ 1784732519833272320
author Miyamoto, Shunsuke
Tanaka, Tomohito
Hirosuna, Kensuke
Nishie, Ruri
Ueda, Shoko
Hashida, Sousuke
Terada, Shinichi
Konishi, Hiromi
Kogata, Yuhei
Taniguchi, Kohei
Komura, Kazumasa
Ohmichi, Masahide
author_facet Miyamoto, Shunsuke
Tanaka, Tomohito
Hirosuna, Kensuke
Nishie, Ruri
Ueda, Shoko
Hashida, Sousuke
Terada, Shinichi
Konishi, Hiromi
Kogata, Yuhei
Taniguchi, Kohei
Komura, Kazumasa
Ohmichi, Masahide
author_sort Miyamoto, Shunsuke
collection PubMed
description SIMPLE SUMMARY: The rate of total tumor engraftment of patient-derived xenografts is 50% in cervical cancer. These cancers retain their histopathological characteristics. The gene mutations and expression patterns associated with carcinogenesis and infiltration and the expression levels of genes in extracellular vesicles released from the tumors are similar between patient-derived xenograft models and primary tumors. Patient-derived xenograft models of cervical cancer could be potentially useful tools for translational research. ABSTRACT: Patient-derived xenograft (PDX) models are useful tools for preclinical drug evaluation, biomarker identification, and personalized medicine strategies, and can be developed by the heterotopic or orthotopic grafting of surgically resected tumors into immunodeficient mice. We report the PDX models of cervical cancer and demonstrate the similarities among original and different generations of PDX tumors. Fresh tumor tissues collected from 22 patients with primary cervical cancer were engrafted subcutaneously into NOD.CB17-PrkdcSCID/J mice. Histological and immunohistochemical analyses were performed to compare primary and different generations of PDX tumors. DNA and RNA sequencing were performed to verify the similarity between the genetic profiles of primary and PDX tumors. Total RNA in extracellular vesicles (EVs) released from primary and PDX tumors was also quantified to evaluate gene expression. The total tumor engraftment rate was 50%. Histologically, no major differences were observed between the original and PDX tumors. Most of the gene mutations and expression patterns related to carcinogenesis and infiltration were similar between the primary tumor and xenograft. Most genes associated with carcinogenesis and infiltration showed similar expression levels in the primary tumor and xenograft EVs. Therefore, compared with primary tumors, PDX models could be potentially more useful for translational research.
format Online
Article
Text
id pubmed-9221029
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-92210292022-06-24 Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization Miyamoto, Shunsuke Tanaka, Tomohito Hirosuna, Kensuke Nishie, Ruri Ueda, Shoko Hashida, Sousuke Terada, Shinichi Konishi, Hiromi Kogata, Yuhei Taniguchi, Kohei Komura, Kazumasa Ohmichi, Masahide Cancers (Basel) Article SIMPLE SUMMARY: The rate of total tumor engraftment of patient-derived xenografts is 50% in cervical cancer. These cancers retain their histopathological characteristics. The gene mutations and expression patterns associated with carcinogenesis and infiltration and the expression levels of genes in extracellular vesicles released from the tumors are similar between patient-derived xenograft models and primary tumors. Patient-derived xenograft models of cervical cancer could be potentially useful tools for translational research. ABSTRACT: Patient-derived xenograft (PDX) models are useful tools for preclinical drug evaluation, biomarker identification, and personalized medicine strategies, and can be developed by the heterotopic or orthotopic grafting of surgically resected tumors into immunodeficient mice. We report the PDX models of cervical cancer and demonstrate the similarities among original and different generations of PDX tumors. Fresh tumor tissues collected from 22 patients with primary cervical cancer were engrafted subcutaneously into NOD.CB17-PrkdcSCID/J mice. Histological and immunohistochemical analyses were performed to compare primary and different generations of PDX tumors. DNA and RNA sequencing were performed to verify the similarity between the genetic profiles of primary and PDX tumors. Total RNA in extracellular vesicles (EVs) released from primary and PDX tumors was also quantified to evaluate gene expression. The total tumor engraftment rate was 50%. Histologically, no major differences were observed between the original and PDX tumors. Most of the gene mutations and expression patterns related to carcinogenesis and infiltration were similar between the primary tumor and xenograft. Most genes associated with carcinogenesis and infiltration showed similar expression levels in the primary tumor and xenograft EVs. Therefore, compared with primary tumors, PDX models could be potentially more useful for translational research. MDPI 2022-06-16 /pmc/articles/PMC9221029/ /pubmed/35740635 http://dx.doi.org/10.3390/cancers14122969 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Miyamoto, Shunsuke
Tanaka, Tomohito
Hirosuna, Kensuke
Nishie, Ruri
Ueda, Shoko
Hashida, Sousuke
Terada, Shinichi
Konishi, Hiromi
Kogata, Yuhei
Taniguchi, Kohei
Komura, Kazumasa
Ohmichi, Masahide
Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization
title Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization
title_full Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization
title_fullStr Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization
title_full_unstemmed Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization
title_short Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization
title_sort validation of a patient-derived xenograft model for cervical cancer based on genomic and phenotypic characterization
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221029/
https://www.ncbi.nlm.nih.gov/pubmed/35740635
http://dx.doi.org/10.3390/cancers14122969
work_keys_str_mv AT miyamotoshunsuke validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT tanakatomohito validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT hirosunakensuke validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT nishieruri validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT uedashoko validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT hashidasousuke validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT teradashinichi validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT konishihiromi validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT kogatayuhei validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT taniguchikohei validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT komurakazumasa validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization
AT ohmichimasahide validationofapatientderivedxenograftmodelforcervicalcancerbasedongenomicandphenotypiccharacterization